Audrey Gabelle

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6055941/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial. Lancet Neurology, The, 2017, 16, 377-389.	10.2	576
2	APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: A genetic screening study of familial and sporadic cases. PLoS Medicine, 2017, 14, e1002270.	8.4	358
3	A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease. Nature Medicine, 2020, 26, 398-407.	30.7	351
4	A Meta-Analysis of Human Embryonic Stem Cells Transcriptome Integrated into a Web-Based Expression Atlas. Stem Cells, 2007, 25, 961-973.	3.2	305
5	Demographic, neurological and behavioural characteristics and brain perfusion SPECT in frontal variant of frontotemporal dementia. Brain, 2006, 129, 3051-3065.	7.6	158
6	<i>SQSTM1</i> Mutations in French Patients With Frontotemporal Dementia or Frontotemporal Dementia With Amyotrophic Lateral Sclerosis. JAMA Neurology, 2013, 70, 1403-10.	9.0	153
7	C9orf72 repeat expansions are a rare genetic cause of parkinsonism. Brain, 2013, 136, 385-391.	7.6	143
8	Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer's disease and PET amyloid-positive patient identification. Alzheimer's Research and Therapy, 2020, 12, 26.	6.2	138
9	Contribution to Alzheimer's disease risk of rare variants in TREM2, SORL1, and ABCA7 in 1779 cases and 1273 controls. Neurobiology of Aging, 2017, 59, 220.e1-220.e9.	3.1	116
10	The French Series of Autosomal Dominant Early Onset Alzheimer's Disease Cases: Mutation Spectrum and Cerebrospinal Fluid Biomarkers. Journal of Alzheimer's Disease, 2012, 30, 847-856.	2.6	113
11	Memantine in Behavioral Variant Frontotemporal Dementia: Negative Results. Journal of Alzheimer's Disease, 2011, 23, 749-759.	2.6	107
12	Differential Mass Spectrometry Profiles of Tau Protein in the Cerebrospinal Fluid of Patients with Alzheimer's Disease, Progressive Supranuclear Palsy, and Dementia with Lewy Bodies. Journal of Alzheimer's Disease, 2016, 51, 1033-1043.	2.6	104
13	Plasma amyloid levels within the Alzheimer's process and correlations with central biomarkers. Alzheimer's and Dementia, 2018, 14, 858-868.	0.8	103
14	Cerebrospinal fluid amyloid-β 42/40 ratio in clinical setting of memory centers: a multicentric study. Alzheimer's Research and Therapy, 2015, 7, 30.	6.2	101
15	SORL1 rare variants: a major risk factor for familial early-onset Alzheimer's disease. Molecular Psychiatry, 2016, 21, 831-836.	7.9	96
16	Risk of Alzheimer's Disease Biological Misdiagnosis Linked to Cerebrospinal Collection Tubes. Journal of Alzheimer's Disease, 2012, 31, 13-20.	2.6	94
17	Tau Protein Quantification in Human Cerebrospinal Fluid by Targeted Mass Spectrometry at High Sequence Coverage Provides Insights into Its Primary Structure Heterogeneity. Journal of Proteome Research, 2016, 15, 667-676.	3.7	91
18	Clinical proteomics of the cerebrospinal fluid: Towards the discovery of new biomarkers. Proteomics - Clinical Applications, 2008, 2, 428-436.	1.6	88

#	Article	IF	CITATIONS
19	Seizures in dominantly inherited Alzheimer disease. Neurology, 2016, 87, 912-919.	1.1	81
20	Screening of dementia genes by whole-exome sequencing in early-onset Alzheimer disease: input and lessons. European Journal of Human Genetics, 2016, 24, 710-716.	2.8	77
21	Cerebrospinal fluid levels of orexin-A and histamine, and sleep profile within the Alzheimer process. Neurobiology of Aging, 2017, 53, 59-66.	3.1	76
22	Correlations between soluble α/β forms of amyloid precursor protein and Aβ38, 40, and 42 in human cerebrospinal fluid. Brain Research, 2010, 1357, 175-183.	2.2	69
23	Adherence to multidomain interventions for dementia prevention: Data from the FINGER and MAPT trials. Alzheimer's and Dementia, 2019, 15, 729-741.	0.8	68
24	Decreased sAβPPβ, Aβ38, and Aβ40 Cerebrospinal Fluid Levels in Frontotemporal Dementia. Journal of Alzheimer's Disease, 2011, 26, 553-563.	2.6	65
25	Interest of CSF biomarker analysis in possible cerebral amyloid angiopathy cases defined by the modified Boston criteria. Journal of Neurology, 2012, 259, 2429-2433.	3.6	65
26	Intersite variability of CSF Alzheimer's disease biomarkers in clinical setting. Alzheimer's and Dementia, 2013, 9, 406-413.	0.8	63
27	Relevance of Aβ42/40 Ratio for Detection of Alzheimer Disease Pathology in Clinical Routine: The PLMR Scale. Frontiers in Aging Neuroscience, 2018, 10, 138.	3.4	59
28	Impact of harmonization of collection tubes on Alzheimer's disease diagnosis. , 2014, 10, S390-S394.e2.		58
29	Long-term exposure to ambient air pollution and risk of dementia: Results of the prospective Three-City Study. Environment International, 2021, 148, 106376.	10.0	58
30	Impact of cerebro-spinal fluid biomarkers of Alzheimer's disease in clinical practice: a multicentric study. Journal of Neurology, 2014, 261, 144-151.	3.6	56
31	HIV Neuroinfection and Alzheimer's Disease: Similarities and Potential Links?. Frontiers in Cellular Neuroscience, 2018, 12, 307.	3.7	56
32	Validation of AclarusDxâ,,¢, a Blood-Based Transcriptomic Signature for the Diagnosis of Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 32, 169-181.	2.6	54
33	Impact of the 2008–2012 French Alzheimer Plan on the Use of Cerebrospinal Fluid Biomarkers in Research Memory Center: The PLM Study. Journal of Alzheimer's Disease, 2013, 34, 297-305.	2.6	51
34	Pathogenic p62/SQSTM1 mutations impair energy metabolism through limitation of mitochondrial substrates. Scientific Reports, 2017, 7, 1666.	3.3	51
35	Cerebrospinal Fluid Collection Tubes: A Critical Issue for Alzheimer Disease Diagnosis. Clinical Chemistry, 2012, 58, 787-789.	3.2	50
36	Can Event-Related Potential Predict the Progression of Mild Cognitive Impairment?. Journal of Clinical Neurophysiology, 2011, 28, 625-632.	1.7	47

#	Article	IF	CITATIONS
37	Cognitive and imaging markers in non-demented subjects attending a memory clinic: study design and baseline findings of the MEMENTO cohort. Alzheimer's Research and Therapy, 2017, 9, 67.	6.2	45
38	Alzheimer's Disease: Advances in Drug Development. Journal of Alzheimer's Disease, 2018, 65, 3-13.	2.6	45
39	A diagnostic scale for Alzheimer's disease based on cerebrospinal fluid biomarker profiles. Alzheimer's Research and Therapy, 2014, 6, 38.	6.2	44
40	Central Nervous System and Peripheral Inflammatory Processes in Alzheimer's Disease: Biomarker Profiling Approach. Frontiers in Neurology, 2015, 6, 181.	2.4	44
41	Hypocretin and brain β-amyloid peptide interactions in cognitive disorders and narcolepsy. Frontiers in Aging Neuroscience, 2014, 6, 119.	3.4	43
42	Orthostatic Hypotension and Risk of Incident Dementia. Hypertension, 2017, 70, 44-49.	2.7	42
43	Association of Long-Term Diet Quality with Hippocampal Volume: Longitudinal Cohort Study. American Journal of Medicine, 2018, 131, 1372-1381.e4.	1.5	42
44	A Complex Relationship Between Suicide, Dementia, and Amyloid: A Narrative Review. Frontiers in Neuroscience, 2018, 12, 371.	2.8	41
45	Causative Mutations and Genetic Risk Factors in Sporadic Early Onset Alzheimer's Disease Before 51 Years. Journal of Alzheimer's Disease, 2019, 71, 227-243.	2.6	39
46	Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker–based case–control study. PLoS Medicine, 2020, 17, e1003289.	8.4	39
47	SILK studies — capturing the turnover of proteins linked to neurodegenerative diseases. Nature Reviews Neurology, 2019, 15, 419-427.	10.1	37
48	From radioimmunoassay to mass spectrometry: a new method to quantify orexin-A (hypocretin-1) in cerebrospinal fluid. Scientific Reports, 2016, 6, 25162.	3.3	36
49	Antibody-free quantification of seven tau peptides in human CSF using targeted mass spectrometry. Frontiers in Neuroscience, 2015, 9, 302.	2.8	34
50	Cerebrospinal fluid A beta 1–40 peptides increase in Alzheimer's disease and are highly correlated with phospho-tau in control individuals. Alzheimer's Research and Therapy, 2020, 12, 123.	6.2	33
51	Relationships between objectives sleep parameters and brain amyloid load in subjects at risk for Alzheimer's disease: the INSIGHT-preAD Study. Sleep, 2019, 42, .	1.1	32
52	Quantitative detection of amyloid-β peptides by mass spectrometry: state of the art and clinical applications. Clinical Chemistry and Laboratory Medicine, 2015, 53, 1483-93.	2.3	30
53	Cerebrospinal fluid Alzheimer biomarkers can be useful for discriminating dementia with Lewy bodies from Alzheimer's disease at the prodromal stage. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 467-475.	1.9	30
54	Sexâ€specific association between neighborhood characteristics and dementia: The Threeâ€City cohort. Alzheimer's and Dementia, 2018, 14, 473-482.	0.8	29

#	Article	IF	CITATIONS
55	Primary Progressive Aphasia in the Network of French Alzheimer Plan Memory Centers. Journal of Alzheimer's Disease, 2016, 54, 1459-1471.	2.6	28
56	Prion Replication Occurs in Endogenous Adult Neural Stem Cells and Alters Their Neuronal Fate: Involvement of Endogenous Neural Stem Cells in Prion Diseases. PLoS Pathogens, 2013, 9, e1003485.	4.7	27
57	Excessive Sleepiness and Longer Nighttime in Bed Increase the Risk of Cognitive Decline in Frail Elderly Subjects: The MAPT-Sleep Study. Frontiers in Aging Neuroscience, 2017, 9, 312.	3.4	26
58	Intake of Meat, Fish, Fruits, and Vegetables and Long-Term Risk of Dementia and Alzheimer's Disease. Journal of Alzheimer's Disease, 2019, 68, 711-722.	2.6	26
59	Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. Alzheimer's and Dementia, 2022, 18, 1868-1879.	0.8	26
60	Association between serum hepcidin level and restless legs syndrome. Movement Disorders, 2018, 33, 618-627.	3.9	25
61	Cerebrospinal Fluid Alzheimer's Disease Biomarkers in Cerebral Amyloid Angiopathy-Related Inflammation. Journal of Alzheimer's Disease, 2016, 50, 759-764.	2.6	23
62	Neural correlates of episodic memory in the Memento cohort. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 224-233.	3.7	23
63	Primary Progressive Aphasia Associated With <i>GRN</i> Mutations. Neurology, 2021, 97, e88-e102.	1.1	23
64	Diabetes Mellitus and Cognition. Neurology, 2021, 97, e836-e848.	1.1	23
65	Absolute quantification of 35 plasma biomarkers in human saliva using targeted MS. Bioanalysis, 2016, 8, 43-53.	1.5	22
66	Plasma neurofilament light chain is associated with cognitive decline in non-dementia older adults. Scientific Reports, 2021, 11, 13394.	3.3	22
67	Plasma Amyloid-β Levels and Prognosis in Incident Dementia Cases of the 3-City Study. Journal of Alzheimer's Disease, 2012, 33, 381-391.	2.6	21
68	Plasma βâ€amyloid 40 levels are positively associated with mortality risks in the elderly. Alzheimer's and Dementia, 2015, 11, 672-680.	0.8	21
69	Plasma amyloid beta predicts conversion to dementia in subjects with mild cognitive impairment: The BALTAZAR study. Alzheimer's and Dementia, 2022, 18, 2537-2550.	0.8	21
70	Plasma AÎ ² and neurofilament light chain are associated with cognitive and physical function decline in non-dementia older adults. Alzheimer's Research and Therapy, 2020, 12, 128.	6.2	20
71	Semantic loss marks early Alzheimer's diseaseâ€related neurodegeneration in older adults without dementia. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12066.	2.4	20
72	Associations Between Physical Activity, Blood-Based Biomarkers of Neurodegeneration, and Cognition in Healthy Older Adults: The MAPT Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2021, 76, 1382-1390.	3.6	20

#	Article	IF	CITATIONS
73	The prognostic value of theÂTau protein serum level in metastatic breast cancer patients and its correlation with brain metastases. BMC Cancer, 2019, 19, 110.	2.6	20
74	Clinical measurement of Hepcidin-25 in human serum: Is quantitative mass spectrometry up to the job?. EuPA Open Proteomics, 2014, 3, 60-67.	2.5	19
75	Development of new quantitative mass spectrometry and semi-automatic isofocusing methods for the determination of Apolipoprotein E typing. Clinica Chimica Acta, 2016, 454, 33-38.	1.1	19
76	A Clinico-Radiological Study of Cerebral Amyloid Angiopathy-Related Inflammation. Cerebrovascular Diseases, 2019, 48, 38-44.	1.7	19
77	Prospective Associations Between Diffusion Tensor Imaging Parameters and Frailty in Older Adults. Journal of the American Geriatrics Society, 2020, 68, 1050-1055.	2.6	19
78	Biomarker counseling, disclosure of diagnosis and followâ€up in patients with mild cognitive impairment: A European Alzheimer's disease consortium survey. International Journal of Geriatric Psychiatry, 2021, 36, 324-333.	2.7	19
79	Absence of Relationship Between Self-Reported Sleep Measures and Amyloid Load in Elderly Subjects. Frontiers in Neurology, 2019, 10, 989.	2.4	18
80	Reduced brain amyloid burden in elderly patients with narcolepsy type 1. Annals of Neurology, 2019, 85, 74-83.	5.3	18
81	Towards a routine application of Top-Down approaches for label-free discovery workflows. Journal of Proteomics, 2018, 175, 12-26.	2.4	17
82	Anxiety and 10-Year Risk of Incident Dementia—An Association Shaped by Depressive Symptoms: Results of the Prospective Three-City Study. Frontiers in Neuroscience, 2018, 12, 248.	2.8	17
83	What is the clinical impact of cerebrospinal fluid biomarkers on final diagnosis and management in patients with mild cognitive impairment in clinical practice? Results from a nation-wide prospective survey in France. BMJ Open, 2019, 9, e026380.	1.9	17
84	Systemic Delivery of siRNA Down Regulates Brain Prion Protein and Ameliorates Neuropathology in Prion Disorder. PLoS ONE, 2014, 9, e88797.	2.5	16
85	Cerebrospinal Fluid Alzheimer's Disease Biomarkers in Isolated Supratentorial Cortical Superficial Siderosis. Journal of Alzheimer's Disease, 2016, 54, 1291-1295.	2.6	16
86	Are migraine and nonâ€migrainous headache risk factors for stroke in the elderly? Findings from a 12â€year cohort followâ€up. European Journal of Neurology, 2016, 23, 1463-1470.	3.3	16
87	Predicting dementia using socio-demographic characteristics and the Free and Cued Selective Reminding Test in the general population. Alzheimer's Research and Therapy, 2017, 9, 21.	6.2	15
88	Red blood cell membrane omega-3 fatty acid levels and physical performance: Cross-sectional data from the MAPT study. Clinical Nutrition, 2018, 37, 1141-1144.	5.0	15
89	Exacerbated CSF abnormalities in younger patients with Alzheimer's disease. Neurobiology of Disease, 2013, 54, 486-491.	4.4	14
90	Clinical relevance of brain atrophy subtypes categorization in memory clinics. Alzheimer's and Dementia, 2021, 17, 641-652.	0.8	14

#	Article	IF	CITATIONS
91	Prodromal characteristics of dementia with Lewy bodies: baseline results of the MEMENTO memory clinics nationwide cohort. Alzheimer's Research and Therapy, 2022, 14, .	6.2	14
92	Lateâ€onset behavioral variant of frontotemporal lobar degenerationÂversus Alzheimer's disease: Interest of cerebrospinal fluidÂbiomarkerÂratios. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 371-379.	2.4	13
93	Isolated parkinsonism is an atypical presentation of GRN and C9orf72 gene mutations. Parkinsonism and Related Disorders, 2020, 80, 73-81.	2.2	13
94	Sleep and dementia. Journal of Nutrition, Health and Aging, 2010, 14, 201-202.	3.3	12
95	Biomarkers of Alzheimer's disease: The present and the future. Revue Neurologique, 2013, 169, 719-723.	1.5	12
96	Time Orientation and 10 Years Risk ofÂDementia in Elderly Adults: TheÂThree-City Study. Journal of Alzheimer's Disease, 2016, 53, 1411-1418.	2.6	12
97	Quantification of hepcidin-25 in human cerebrospinal fluid using LC–MS/MS. Bioanalysis, 2017, 9, 337-347.	1.5	12
98	Identification of multiple proteoforms biomarkers on clinical samples by routine Top-Down approaches. Data in Brief, 2018, 18, 1013-1021.	1.0	12
99	Influence of activity space on the association between neighborhood characteristics and dementia risk: results from the 3-City study cohort. BMC Geriatrics, 2019, 19, 4.	2.7	12
100	Investigating the association between cancer and the risk of dementia: Results from the Memento cohort. Alzheimer's and Dementia, 2021, 17, 1415-1421.	0.8	12
101	Complaints of daytime sleepiness, insomnia, hypnotic use, and risk of dementia: a prospective cohort study in the elderly. Alzheimer's Research and Therapy, 2022, 14, 12.	6.2	12
102	Autoantibody profiling on high-density protein microarrays for biomarker discovery in the cerebrospinal fluid. Journal of Immunological Methods, 2008, 338, 75-78.	1.4	11
103	Initial Memory Deficit Profiles in Patients with a Cerebrospinal Fluid Alzheimer's Disease Signature. Journal of Alzheimer's Disease, 2014, 41, 1109-1116.	2.6	11
104	Biological and Neuroimaging Markers as Predictors of 5-Year Incident Frailty in Older Adults: A Secondary Analysis of the MAPT Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2021, 76, e361-e369.	3.6	11
105	<i>MAPT</i> R406W increases tau T217 phosphorylation in absence of amyloid pathology. Annals of Clinical and Translational Neurology, 2021, 8, 1817-1830.	3.7	11
106	Stable Isotope Labeling by Amino acid <i>in Vivo</i> (SILAV): a new method to explore protein metabolism. Rapid Communications in Mass Spectrometry, 2015, 29, 1917-1925.	1.5	10
107	Somatostatin and Neuropeptide Y in Cerebrospinal Fluid: Correlations With Amyloid Peptides Aβ1–42 and Tau Proteins in Elderly Patients With Mild Cognitive Impairment. Frontiers in Aging Neuroscience, 2018, 10, 297.	3.4	10
108	Cross-sectional associations between cortical thickness and physical activity in older adults with spontaneous memory complaints: The MAPT Study. Journal of Sport and Health Science, 2023, 12, 324-332.	6.5	10

#	Article	IF	CITATIONS
109	Plasma MCP-1 and changes on cognitive function in community-dwelling older adults. Alzheimer's Research and Therapy, 2022, 14, 5.	6.2	10
110	Cerebrospinal Fluid and Plasma Biomarkers do not Differ in the Presenile and Late-Onset Behavioral Variants of Frontotemporal Dementia. Journal of Alzheimer's Disease, 2020, 74, 903-911.	2.6	9
111	Amyloid imaging in Alzheimer's disease: A literature review. Journal of Nutrition, Health and Aging, 2014, 18, 723-740.	3.3	8
112	Development and validation of dried matrix spot sampling for the quantitative determination of amyloid β peptides in cerebrospinal fluid. Clinical Chemistry and Laboratory Medicine, 2014, 52, 649-55.	2.3	8
113	Can we rely only on ratios of cerebrospinal fluid biomarkers for AD biological diagnosis?. Alzheimer's and Dementia, 2015, 11, 1125-1126.	0.8	8
114	Defining Vitality: Associations of Three Operational Definitions of Vitality with Disability in Instrumental Activities of Daily Living and Frailty among Elderly Over a 3-Year Follow-Up (MAPT Study). Journal of Nutrition, Health and Aging, 2019, 23, 386-392.	3.3	8
115	A Pragmatic, Data-Driven Method to Determine Cutoffs for CSF Biomarkers of Alzheimer Disease Based on Validation Against PET Imaging. Neurology, 2022, 99, .	1.1	8
116	Palmomental Reflex a Relevant Sign in Early Alzheimer's Disease Diagnosis?. Journal of Alzheimer's Disease, 2016, 49, 1135-1141.	2.6	7
117	Generation of induced pluripotent stem cells (IRMBi001-A) from an Alzheimer's disease patient carrying a G217D mutation in the PSEN1 gene. Stem Cell Research, 2019, 34, 101381.	0.7	7
118	Subjective cognitive and non ognitive complaints and brain MRI biomarkers in the MEMENTO cohort. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12051.	2.4	7
119	Prospective associations between physical activity levels and white matter integrity in older adults: results from the MAPT study. Maturitas, 2020, 137, 24-29.	2.4	7
120	Socioeconomic inequalities in dementia risk among a French population-based cohort: quantifying the role of cardiovascular health and vascular events. European Journal of Epidemiology, 2021, 36, 1015-1023.	5.7	7
121	Blood amyloid and tau biomarkers as predictors of cerebrospinal fluid profiles. Journal of Neural Transmission, 2022, 129, 231-237.	2.8	7
122	Neurodegenerative dementia and Parkinsonism. Journal of Nutrition, Health and Aging, 2010, 14, 37-44.	3.3	6
123	In Vivo Large-Scale Mapping of Protein Turnover in Human Cerebrospinal Fluid. Analytical Chemistry, 2019, 91, 15500-15508.	6.5	6
124	Relevance of Follow-Up in Patients with Core Clinical Criteria for Alzheimer Disease and Normal CSF Biomarkers. Current Alzheimer Research, 2018, 15, 691-700.	1.4	5
125	Characteristics of Bipolar Patients with Cognitive Impairment of Suspected Neurodegenerative Origin: A Multicenter Cohort. Journal of Personalized Medicine, 2021, 11, 1183.	2.5	5
126	How to optimize the use of biobanks from population-based cohorts in aging research. Biogerontology, 2016, 17, 221-227.	3.9	4

#	Article	IF	CITATIONS
127	Cognitive Event-Related Potential, an Early Diagnosis Biomarker in Frail Elderly Subjects: The ERP-MAPT-PLUS Ancillary Study. Journal of Alzheimer's Disease, 2017, 58, 87-97.	2.6	4
128	Re: Prospective Associations between Diffusion Tensor Imaging Parameters and Frailty in Older Adults. Journal of the American Geriatrics Society, 2023, 71, .	2.6	4
129	Development and Validation of a Cutoff for the Chair Stand Test as a Screening for Mobility Impairment in the Context of the Integrated Care for Older People Program. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2023, 78, 104-110.	3.6	4
130	Explaining the association between social and lifestyle factors and cognitive functions: a pathway analysis in the Memento cohort. Alzheimer's Research and Therapy, 2022, 14, 68.	6.2	4
131	Meal-related difficulties and weight loss in older people: Longitudinal data from MAPT study. Clinical Nutrition, 2020, 39, 3483-3488.	5.0	3
132	Amyloid Burden and Depressive Symptom Trajectories in Older Adults at Risk of Developing Cognitive Decline. Journal of Clinical Psychiatry, 2021, 82, .	2.2	3
133	Investigating the combination of plasma amyloid-beta and geroscience biomarkers on the incidence of clinically meaningful cognitive decline in older adults. GeroScience, 2022, 44, 1489-1503.	4.6	3
134	Five‥ear Lower Extremity Function is Associated with White Matter Abnormality in Older Adults. Journal of the American Geriatrics Society, 2021, 69, 995-1002.	2.6	2
135	Healthcare Costs Associated with Potentially Inappropriate Medication Prescribing Detected by Computer Algorithm Among Older Patients. Drugs and Aging, 2022, 39, 367-375.	2.7	2
136	Analytical challenges related to the use of biomarker ratios for the biological diagnosis of Alzheimer's disease. Clinical Chemistry and Laboratory Medicine, 2015, 53, e175-7.	2.3	1
137	Collaborative efforts to prevent Alzheimer's disease. Journal of Nutrition, Health and Aging, 2017, 21, 1072-1074.	3.3	1
138	FATTY ACIDS AND ALZHEIMER'S DISEASE: EVIDENCE ON COGNITION AND CORTICAL ?-AMYLOID FROM SECONDARY ANALYSES OF THE MULTIDOMAIN ALZHEIMER PREVENTIVE TRIAL. journal of prevention of Alzheimer's disease, The, 2018, 5, 1-3.	2.7	1
139	Ready-meal consumption in older people: association with obesity and dietary intake. Aging Clinical and Experimental Research, 2019, 31, 855-861.	2.9	1
140	Cross-sectional and longitudinal interaction effects of physical activity and APOE-ε4 on white matter integrity in older adults: The MAPT study. Maturitas, 2021, 152, 10-19.	2.4	1
141	Physical activity, body mass index, and blood progranulin in older adults: cross-sectional associations in the MAPT study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2022, , .	3.6	1
142	Sulcal morphology as cognitive decline predictor in older adults with memory complaints. Neurobiology of Aging, 2022, 113, 84-94.	3.1	1
143	Stable Isotope Labeling Kinetics in CNS Translational Medicine: Introduction to SILK Technology. Handbook of Behavioral Neuroscience, 2019, 29, 173-190.	0.7	0
144	Immunoassay and Mass Spectrometry Methods for Tau Protein Quantification in the Cerebrospinal Fluid. Neuromethods, 2021, , 71-85.	0.3	0

#	Article	IF	CITATIONS
145	Imagerie métabolique et moléculaire : l'exemple des maladies neurodégénératives. Bulletin De L'Academie Nationale De Medecine, 2018, 202, 1511-1521.	0.0	0
146	Title is missing!. , 2020, 17, e1003289.		0
147	Title is missing!. , 2020, 17, e1003289.		0
148	Title is missing!. , 2020, 17, e1003289.		0
149	Title is missing!. , 2020, 17, e1003289.		0
150	Title is missing!. , 2020, 17, e1003289.		0
151	Title is missing!. , 2020, 17, e1003289.		0
152	Title is missing!. , 2020, 17, e1003289.		0